Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, Sara A. Hurvitz
Clinical Cancer Research (2018) Vol. 24, Iss. 21, pp. 5206-5218
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 4, pp. 307-316
Open Access | Times Cited: 833
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen‐Shen Lu, Seock‐Ah Im, Marco Colleoni, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 5, pp. 851-859
Open Access | Times Cited: 170
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Xueqing Wang, Shanshan Zhao, Qinghan Xin, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 9, pp. 1283-1291
Open Access | Times Cited: 41
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer
Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2812-2821
Open Access | Times Cited: 20
Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
Marek Samec, Alena Líšková, Lenka Koklesová, et al.
The EPMA Journal (2020) Vol. 11, Iss. 3, pp. 377-398
Open Access | Times Cited: 115
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 12, pp. 1750-1759
Closed Access | Times Cited: 109
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
Ludi Yang, Ruobing Jia, Tongxin Ge, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 54
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Lu-Qi Cao, Haidong Sun, Yuhao Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Hee Kyung Ahn, Ji‐Yeon Kim, Kyung-Hun Lee, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 3, pp. 343-354
Closed Access | Times Cited: 1
Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
Rola El Sayed, Lara El Jamal, Sarah El Iskandarani, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 54
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Nadia Harbeck, Fábio Franke, Rafael Villanueva-Vázquez, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 52
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Vincenzo Di Lauro, Giacomo Barchiesi, Federica Martorana, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100629-100629
Open Access | Times Cited: 31
Feasibility and acceptability of offering breast cancer risk assessment to general population women aged 30–39 years: a mixed-methods study protocol
Sarah Hindmarch, Sacha J. Howell, Juliet A. Usher‐Smith, et al.
BMJ Open (2024) Vol. 14, Iss. 1, pp. e078555-e078555
Open Access | Times Cited: 6
Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach
Erik Kúdela, Marek Samec, Peter Kubatka, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1791-1791
Open Access | Times Cited: 47
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
Mariko DeWire‐Schottmiller, Christine Fuller, Trent R. Hummel, et al.
Journal of Neuro-Oncology (2020) Vol. 149, Iss. 3, pp. 511-522
Closed Access | Times Cited: 37
Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Winnie Yeo, Takayuki Ueno, Ching‐Hung Lin, et al.
Breast Cancer Research and Treatment (2019) Vol. 177, Iss. 3, pp. 549-559
Closed Access | Times Cited: 35
Breast cancer: an update on treatment-related infertility
Erica Silvestris, Miriam Dellino, Paola Cafforio, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 146, Iss. 3, pp. 647-657
Closed Access | Times Cited: 34
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
Ying Fan, Tao Sun, Zhimin Shao, et al.
JAMA Oncology (2021) Vol. 7, Iss. 10, pp. e213428-e213428
Open Access | Times Cited: 30
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Patrick Neven, Hope S. Rugo, Sara M. Tolaney, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 28
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 1408-1420
Open Access | Times Cited: 28
Prevalence and Relevance of Vitamin D Deficiency in Newly Diagnosed Breast Cancer Patients: A Pilot Study
Cosima Zemlin, Laura Altmayer, Caroline Stuhlert, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1450-1450
Open Access | Times Cited: 11
Contemporary Review of the Management and Treatment of Young Breast Cancer Patients
Brooke Vuong, Ana I Jacinto, Sharon B. Chang, et al.
Clinical Breast Cancer (2024)
Closed Access | Times Cited: 4
A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
Elizabeth Magno, Karen M. Bussard
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3407-3407
Open Access | Times Cited: 3
Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
Ami N. Shah, Otto Metzger, Cynthia Huang Bartlett, et al.
The Oncologist (2020) Vol. 25, Iss. 6, pp. e900-e908
Open Access | Times Cited: 27
Machilin D, a Lignin Derived from Saururus chinensis, Suppresses Breast Cancer Stem Cells and Inhibits NF-κB Signaling
Zhen Xing, Hack Sun Choi, Ji Hyang Kim, et al.
Biomolecules (2020) Vol. 10, Iss. 2, pp. 245-245
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top